has a unique analgesic property clearly different from that of morphine and it has a propensity to produce spinal analgesia.
Introduction

H-Dmt-D -Arg-Phe-Lys-NH 2 ([Dmt
]DALDA) is a dermorphin-derived tetrapeptide with extraordinary selectivity for the -opioid receptor [1] . It carries a net positive charge of 3+ at physiological pH. Despite its polar nature, [Dmt 1 ]DALDA is readily distributed to the CNS and produces long-lasting analgesic effects after systemic administration [2] . [Dmt 1 ]DALDA also produces very potent analgesic effects after intrathecal administration [3] , but is much less potent after intracerebroventricular (i.c.v.) administration [2] . In this regard, it differs from the prototypical -agonist, morphine, which is equally potent after intrathecal and i.c.v. administration. Thus, [Dmt 1 ]-DALDA and morphine appear to have differential analgesic characteristics even though they are both -opioid agonists acting in the CNS. To further characterize the 1 ]DALDA), a highly selective -opioid peptide, is potently analgesic after systemic and intrathecal administration but is less potent given intracerebroventricularly. This study was performed to further characterize the analgesic effects of [ ]DALDA and morphine, we compared the effects of the two compounds after systemic administration in two different acute pain tests, the tail flick test and the paw withdrawal test. The tail flick test has been widely used in evaluating analgesic effects of opioids. It utilizes a spinal reflex induced by a pain stimulus and, in theory, the CNS actions of analgesics being examined in this test either involve the spinal cord directly or involve descending analgesic pathways to the spinal cord [4] . On the other hand, the hot plate test involves both spinal and supraspinal pathways, and the site of action of analgesic agents in this assay system may be at any level of the pain pathway [4] . A difference in analgesic potency of an opioid agonist in the two tests may reflect its distinctive site or mode of action. To the best of our knowledge, there have been no reports on an opioid agonist that has differential effects in these two tests. In addition, to further investigate the differential effects of [Dmt 1 ]DALDA and morphine, it was examined how antagonizing their spinal opioid actions would affect analgesic activity.
Materials and Methods
Experiments were performed according to the guidelines of the Guide for the Care and Use of Laboratory Animals, as adopted and promulgated by the United States National Institutes of Health, and were approved by the Institutional Animal Use Committee of the Chiba University Graduate School of Medicine.
Animals and Drugs
Male Sprague-Dawley rats (180-200 g) were used in the experiments. [Dmt 1 ]DALDA was synthesized as described elsewhere [1] . Morphine hydrochloride and naloxone hydrochloride were obtained from Takeda Pharmaceuticals, Osaka, Japan, and Sigma-Aldrich Co., St. Louis, Mo., USA, respectively.
Drug Administration
For subcutaneous (s.c.) administration, [Dmt 1 ]DALDA or morphine were dissolved in saline and were delivered in a volume of 0.1 ml/100 g rat weight. Subcutaneous administration was performed 2 h ([Dmt 1 ]DALDA) or 30 min (morphine) prior to pain testing. Spinal administration of naloxone or saline was carried out under light sevoflurane anesthesia by direct intrathecal injection at the level of L 2/3 via a 30-gauge needle connected to a polyethylene tube using a Hamilton syringe. Spinal injection was performed 10 min prior to pain testing in a volume of 10 l.
Tail Flick and Hot Plate Tests
For the tail flick test, radiant heat was applied to the tail at 5 cm from the tip using a tail flick apparatus (IITC, Woodland Hills, Calif., USA). The time from the onset of the heat to the withdrawal of the tail (tail flick latency) was measured. The intensity of the radiant heat was adjusted so that baseline latencies would fall between 2.5 and 3.5 s. To avoid tissue damage, the heat stimulus was discontinued after 10 s (cut-off latency). For the hot plate test, rats were placed on a 52 ° C hot plate (Nissin Scientific Corp., Tokyo, Japan) and the latency to paw lick was recorded. A cut-off time was set at 30 s. Baseline latencies for both tests were obtained for each animal prior to the administration of the drug. In both tests, response latencies of each animal were determined at the time of peak effect of the drug administered (2 h for [Dmt 1 ]DALDA and 30 min for morphine).
Data Analysis
Response latencies in the tail flick and hot plate tests were expressed as percentage of baseline values. A one-way ANOVA was used for statistical analysis. A p value ! 0.05 was considered significant.
Results
Analgesic Effects in Acute Pain Tests
Morphine showed potent dose-dependent analgesic effects in both the tail flick test and the hot plate test ( fig. 1 ) ]DALDA or morphine analgesia was observed in both pain tests by spinally injecting the same volume of saline ( fig. 2 , 3 ) . Naloxone pretreatment itself did not affect tail flick or hot plate latency ( fig. 2 , 3 ) . 
Discussion
The tail flick test utilizes a spinal reflex induced by a pain stimulus, thus theoretically, the CNS actions produced by analgesic agents in this test directly involve the spinal cord or activate descending analgesic pathways to the spinal cord [4] . On the other hand, the hot plate test involves both spinal and supraspinal pathways, and the site of action of analgesic agents that affect this test may be at any level of the pain pathway [4] . Both the tail flick and hot plate tests are highly sensitive to opioids and have been widely utilized to demonstrate opioid analgesia in animal studies. The systemic administration of the prototypical -opioid agonist morphine has been shown to produce analgesia in both pain tests [5, 6] . In agreement with these earlier works, in the present study, we observed potent dose-dependent analgesic effects of morphine in the two tests at the same dose level. On the other hand, we found that systemic administration of [Dmt 1 ]DALDA was markedly more effective in the tail flick test than in the hot plate test. Doses that produced potent analgesic effects in the tail flick test elicited no analgesic effect in the hot plate test. Furthermore, the opioid receptor antagonist naloxone given spinally completely abolished the analgesic effect of systemic [ ]DALDA differentially activated different -receptor variants as compared to the selective -agonist DAMGO [9] .
We found that [Dmt 1 ]DALDA at high doses, as compared to the low doses required in the tail flick test, produced an analgesic effect in the hot plate test which was only partially blocked by spinal naloxone. Thus, at these high doses, [Dmt 1 ]DALDA can act similarly to morphine by blocking nociceptive pathways involved in the hot plate test and exerting analgesic action in the brain as well as in the spinal cord. However, lower doses of this compound that produced a potent effect in the tail flick test had no effect in the hot plate test. This greater potency in the tail flick test as compared to the hot plate test cannot be explained simply by the propensity of ]DALDA in the two tests seems to suggest that the nociceptive transmissions are not uniform and that they may be differentially affected by drugs. Although both pain tests are based on thermal nociception, there is a difference in the pain stimuli between the two tests. In general, the hot plate test utilizes a lower intensity thermal stimulation that results in a longer latency for the animal to react as compared to the tail flick test. Such difference in stimulus intensity may activate different pathways in the spinal cord. We have previously shown that neuronal endothelin-1 has an effect in the tail flick test only when the stimulus intensity is markedly decreased [10] ]DALDA may be effective in pathological pain involving spinal mechanisms, in particular neuropathic pain. On the other hand, the mechanism that produces its relatively low effect in the hot plate test may result in relative ineffectiveness in clinical pain. Although morphine and other opioids are effective in neuropathic pain, high doses are frequently required that may be intolerable clinically. It remains to be shown whether [Dmt 1 ]DALDA may be more effective than morphine in neuropathic pain due to its propensity to act in the spinal cord, and also due to its non-opioid actions such as norepinephrine reuptake inhibition and ROS scavenging actions [11] .
